Shopping Cart
- Remove All
Your shopping cart is currently empty
Ipragliflozin (ASP1941) is under investigation in Type 2 Diabetes and Diabetes Mellitus, Type 2.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $52 | In Stock | |
| 50 mg | $84 | In Stock | |
| 100 mg | $137 | In Stock | |
| 200 mg | $218 | In Stock | |
| 500 mg | $462 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $48 | In Stock |
| Description | Ipragliflozin (ASP1941) is under investigation in Type 2 Diabetes and Diabetes Mellitus, Type 2. |
| Targets&IC50 | SGLT2 (rat):6.73 nM, SGLT2 (human):7.4 nM, SGLT2:5.64 nM, SGLT1 (rat):1166 nM, SGLT1 (mouse):1380 nM, SGLT1 (human):1876 nM |
| Kinase Assay | Inhibition of TNF-α synthesis: TNF-α inhibitory activity is measured in lipopolysacharide (LPS) stimulated PBMC. Pomalidomide is added to human PBMCs 1 hour prior to the addition of LPS (1 μg/mL) and incubation continued for an additional 18-20 hours. Supernatants are then harvested, and the concentration of TNF-α in the supernatants is determined by ELISA. The concentration of Pomalidomide that inhibits TNF- production by 50% (IC50) is calculated by nonlinear regression analysis. The human whole blood TNF- inhibition assay is run in a similar fashion to the PBMC assay except that heparinized fresh human whole blood is plated directly into microtiter plates. |
| Synonyms | ASP1941 |
| Molecular Weight | 404.45 |
| Formula | C21H21FO5S |
| Cas No. | 761423-87-4 |
| Smiles | O[C@H]1[C@@H](O[C@H](CO)[C@@H](O)[C@@H]1O)C2=CC(CC3=CC=4C(S3)=CC=CC4)=C(F)C=C2 |
| Relative Density. | 1.452 g/cm3 |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 70 mg/mL (173.07 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.94 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.